Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 214,800 shares, an increase of 116.5% from the November 15th total of 99,200 shares. Based on an average daily volume of 249,100 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ENLV shares. EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Enlivex Therapeutics in a research report on Friday, September 27th.

Enlivex Therapeutics Price Performance

Shares of NASDAQ:ENLV opened at $1.20 on Friday. The business’s 50-day moving average is $1.29 and its 200 day moving average is $1.34. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.59. The firm has a market capitalization of $25.69 million, a P/E ratio of -1.22 and a beta of 1.01.

Hedge Funds Weigh In On Enlivex Therapeutics

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in Enlivex Therapeutics in the 2nd quarter worth approximately $35,000. Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics in the third quarter worth $50,000. Finally, Armistice Capital LLC purchased a new position in shares of Enlivex Therapeutics in the second quarter worth $2,415,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.